Drug-eluting stents: Current outcomes and potential impact on coronary disease management

Journal of Invasive Cardiology

Volumn 14, Issue 11, 2002, Pages 709-712

  Vetrovec, George W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; PACLITAXEL; RAPAMYCIN; TACROLIMUS; TAXANE DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; HUMAN; RESTENOSIS; TREATMENT OUTCOME;

EID: 0036851935     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Pugh PJ, O'Toole L, Channer KS, et al. Coronary artery bypass surgery versus stenting for multivessel disease. N Engl J Med 2002;345:1641-1643.
2. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implementation in patients with multivessel coronary artery disease. The Stent or Surgery Trial: A randomized controlled trial. Lancet 2002;360:965-970.
3. Wu AH, Parsons L, Every NR, et. al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll Cardiol 2002;40:1389-1394.
4. Morice MC, Serruys PW, Sousa JE, et al., for the RAVEL Study group. A randomized comparison of Sirolimul-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
5. Farb A, John M, Acambado E, et al. Oral everolimus inhibits in-stent neo-intimal growth. Circulation (Online) 2002.